Medical Oncology Unit, University Hospital of Parma, Parma, Italy
Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Anticancer Res. 2014 Jun;34(6):3185-8.
Renal failure in cancer patients is not a rare clinical condition and often contraindicates anticancer drug treatment; moreover, chemotherapeutic drugs are frequently identified as possible iatrogenic cause of renal failure. Molecular therapies, when appropriate, could represent a therapeutic option for cancer patients with severe renal disease, but the lack of knowledge in this field, at present, limits their use in patients undergoing dialysis. Herein we describe a case, at our knowledge the first reported, of a patient with advanced lung adenocarcinoma on maintenance hemodialysis treated with gefitinib and then with afatinib; we also reviewed the literature on epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) used in NSCLC patients with concomitant renal impairment.
癌症患者的肾衰竭并不罕见，常使抗癌药物治疗成为禁忌；此外，化疗药物常被认为是肾衰竭的可能医源性病因。分子疗法在适当的情况下可能成为严重肾脏疾病的癌症患者的治疗选择，但目前该领域的知识匮乏限制了它们在透析患者中的应用。在此，我们描述了一例我们所知的首例接受维持性血液透析的晚期肺腺癌患者，该患者先用吉非替尼治疗，然后用阿法替尼治疗；我们还回顾了有关表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）在合并肾功能不全的 NSCLC 患者中的应用的文献。
